Subcutaneous Allergen Immunotherapy With Hypoallergenic Bet v 1 Compared to Conventional Extract: Poorer Blocking Antibody Capacity Dominated by IgG<sub>1</sub> Instead of IgG<sub>4</sub>.

Allergy · 2025 · PMC12261870 · PMID 40452413

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In case of sIgG 4 , the fold increase ( t = 1 to t = 3) was highly significant for BPE‐AC (13.9‐fold increase for BPE and 20.8‐fold for Bet v 1), and at t = 3, both BPE‐ and Bet v 1‐sIgG 4 were significantly higher compared to placebo t = 3 (Figure 2D ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Subcutaneous Allergen Immunotherapy With Hypoallergenic Bet v 1 Compared to Conventional Extract: Poorer Blocking Antibody Capacity Dominated by IgG&lt;sub&gt;1&lt;/sub&gt; Instead of IgG&lt;sub&gt;4&lt;/sub&gt;.

The sentences

Subcutaneous Allergen Immunotherapy With Hypoallergenic Bet v 1 Compared to Conventional Extract: Poorer Blocking Antibody Capacity Dominated by IgG<sub>1</sub> Instead of IgG<sub>4</sub>.